All News

Screen%20Shot%202019-06-12%20at%204.26.31%20PM.png

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

d Janet Pope, MD, MPH, FRCPC

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

Read Article
BP.jpg

Allopurinol Fails to Curtail Hypertension

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Read Article
IMG_2743.JPG (keep)

EULAR 2019 – Day 3 Report

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

Read Article
US.hand_.jpg

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

d David Liew, FRACP

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rhe

Read Article
EULAR19.abstract.jpg (keep)

EULAR 2019 Report – Day 2

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. It was a full and lively second day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day two at EULAR 2019.

Read Article
Dr. Kevin Winthrop - Expert Advice on TB Testing and Treatment from #EULAR2019 https://t.co/Nz7oKiIjrm

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Gerd Burmester reviews the SEMIRA study that examines whether or not you should wean that 5mg Prednisone in your RA patients. #EULAR2019 https://t.co/Vk0salb8bX

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparison of high and low iris acid levels in a large cohort of gout patients shows high SUA associated with more comorbidities and CKD, more colchicine & indocin use. #EULAR2019 SAT0435 https://t.co/FvUU4Q6Ky9
Dr. John Cush RheumNow ( View Tweet)
Shingrix can be give to inflammatory arthritis pts? Collective report from the Brigham & Women’s Hospital looked at the safety of Shingrix given to 300 RA, PsA, etc patient without any reports of H.Zoster and a 4% rate of "flares". #EULAR2019 FRI0068 https://t.co/Wkx5V9vM8r https://t.co/kErMMU97tB

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis from the BSRBR ankylosing spondylitis registry of 2420 AS pts shows that HLA-B27 is associated with an increased risk of anterior uveitis but a decreased risk of psoriasis and IBD. #Eular2019 OP0262 https://t.co/jslLYkMr9Q
Dr. John Cush RheumNow ( View Tweet)
#Hyperuricemia (HUC) /#gout found to be associated with CVD in a cohort of 37,315 PsA patients. Investigators at Icahn Mt Sinai saw higher rates of Afib and HF (with preserved ejection fraction) in patients with hyperuricemia/gout vs those without. SAT0371 #EULAR2019 @RheumNow https://t.co/98B3JSFSnv
Gout Study Group GoutGroup ( View Tweet)
Good lessons from 22,607 RA patients from the UK CPRD: cataracts and glaucoma from pred are dose dependent, and even 1000mg cumulative dose is enough. That’s equivalent to three months PMR therapy for most #EULAR2019 SAT0592 @dr_rachelblack @CatherineL_Hill @earlyARA @RheumNow https://t.co/AJfBgLdHdb
David Liew drdavidliew ( View Tweet)
Dr. Peter Lipsky - 1 Million #Gout Patients & who cares for them. SAT0435 #EULAR2018 https://t.co/WfFR4tRf2p

Links:

Dr. John Cush RheumNow ( View Tweet)

14 patient pilot study presented by Dr. Genovese; once daily vagal stimulation worked but 4 times daily did not! https://t.co/TUWr7fT7x3

Links:

Dr. John Cush RheumNow ( View Tweet)

FUTURE 5 secukinumab in PsA placebo arm only 12w. Week 52 pt can increase doses from 150mg to 300mg. 2y data presented. Small incremental response when dose is escalated, and radiographic progression is low. #eular2019 @RheumNow

Alberta Hoi tuna0sashimi ( View Tweet)

Men with #gout are severely under treated, under educated and unmotivated to better manage their gout! https://t.co/icdDIUSdJb

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Dinesh Khanna discusses the pulmonary outcomes of tocilizumab is systemic sclerosis (focuSSed trial). #EULAR2019 OP0245 https://t.co/UtvBLz6Cg7 https://t.co/tptDVbBug2

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA (Stills) patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/9mtxPkHZr3
Dr. John Cush RheumNow ( View Tweet)
We need to talk about repeated ANAs - good lessons from the plenary hall today about 7875 repeated ANA tests from a single center. #EULAR2019 OP0020 by Ai Li Yeo @RheumNow @MonashHealth @earlyARA @ChooseWiselyAU https://t.co/j00DDKuZFt
David Liew drdavidliew ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×